| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $305,865 | 3 | 100 |
| MOOS WALTER H | director | 0 | $0 | 1 | $145,440 | $-145,440 |
| Ali-Jackson Kamil | director | 0 | $0 | 2 | $160,425 | $-160,425 |
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; …
Over the last 12 months, insiders at Rigel Pharmaceuticals, Inc. have bought $0 and sold $305,865 worth of Rigel Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rigel Pharmaceuticals, Inc. have bought $688,400 and sold $220,848 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000,000 shares for transaction amount of $688,400 was made by RODRIGUEZ RAUL R (CEO, President) on 2022‑06‑09.
| 2026-06-22 | Sale | Ali-Jackson Kamil | director | 2,500 0.0132% | $35.00 | $87,500 | +28.55% | |
| 2026-05-26 | Sale | Ali-Jackson Kamil | director | 2,500 0.0134% | $29.17 | $72,925 | +48.35% | |
| 2026-02-20 | Sale | MOOS WALTER H | director | 4,000 0.0226% | $36.36 | $145,440 | +4.31% | |
| 2025-02-05 | Sale | RODRIGUEZ RAUL R | CEO, President | 4,400 0.0263% | $21.93 | $96,474 | +19.88% | |
| 2025-02-05 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 1,734 0.0103% | $21.93 | $38,020 | +19.88% | |
| 2025-02-05 | Sale | Santos David A | EVP, Chief Commercial Officer | 1,796 0.0107% | $21.93 | $39,379 | +19.88% | |
| 2025-02-05 | Sale | Furey Raymond J. | EVP, GC, CCO & Corp Sec | 1,339 0.008% | $21.93 | $29,359 | +19.88% | |
| 2025-02-04 | Sale | RODRIGUEZ RAUL R | CEO, President | 4,952 0.0278% | $20.92 | $103,601 | +28.62% | |
| 2025-02-04 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 2,036 0.0114% | $20.92 | $42,595 | +28.62% | |
| 2025-02-04 | Sale | Santos David A | EVP, Chief Commercial Officer | 2,125 0.0119% | $20.92 | $44,457 | +28.62% | |
| 2025-02-04 | Sale | Furey Raymond J. | EVP, GC, CCO & Corp Sec | 1,448 0.0081% | $20.92 | $30,294 | +28.62% | |
| 2024-02-05 | Sale | RODRIGUEZ RAUL R | CEO, President | 30,545 0.016% | $1.14 | $34,821 | +14.62% | |
| 2024-02-05 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 7,027 0.0037% | $1.14 | $8,011 | +14.62% | |
| 2024-02-05 | Sale | Santos David A | EVP, Chief Commercial Officer | 8,918 0.0047% | $1.14 | $10,167 | +14.62% | |
| 2024-02-02 | Sale | RODRIGUEZ RAUL R | CEO, President | 22,349 0.0116% | $1.13 | $25,261 | +17.54% | |
| 2024-02-02 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 5,601 0.0029% | $1.13 | $6,327 | +17.54% | |
| 2024-02-02 | Sale | Santos David A | EVP, Chief Commercial Officer | 5,601 0.0029% | $1.13 | $6,329 | +17.54% | |
| 2023-02-06 | Sale | RODRIGUEZ RAUL R | CEO, President | 20,340 0.012% | $1.75 | $35,595 | -26.90% | |
| 2023-02-02 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 5,389 0.0029% | $1.66 | $8,946 | -28.81% | |
| 2023-02-02 | Sale | Santos David A | EVP, Chief Commercial Officer | 5,388 0.0029% | $1.66 | $8,945 | -28.81% |
| Flynn James E | 10 percent owner | 3204167 17.1531% | $156.56M | 1 | 1 | <0.0001% |
| BVF PARTNERS L P/IL | 10 percent owner | 646559 3.4613% | $31.59M | 1 | 1 | <0.0001% |
| RODRIGUEZ RAUL R | CEO, President | 239454 1.2819% | $11.7M | 2 | 6 | +34.43% |
| Mayer Eldon C. III | EVP & Chief Commercial Officer | 215000 1.151% | $10.5M | 3 | 0 | <0.0001% |
| Schorno Dean L | EVP & Chief Financial Officer | 57235 0.3064% | $2.8M | 1 | 5 | +2.44% |
| Goodwin Bradford S | director | 10000 0.0535% | $488,600.00 | 1 | 0 | +109.25% |
| COOPER ROBIN D G | Sr. V.P. Pharmaceutical Scs. | 9000 0.0482% | $439,740.00 | 5 | 0 | +47.09% |
| Grossbard Elliott B | Sr. VP Medical Development | 2000 0.0107% | $97,720.00 | 1 | 0 | +4.66% |
| VANCE DOLLY | EVP Corp. Affairs, G.C., Sect. | 575 0.0031% | $28,094.50 | 1 | 3 |
$100,473,344 | 83 | 9.53% | $826.91M | |
$15,410,062 | 81 | 39.69% | $975.93M | |
$5,911,307 | 70 | -1.38% | $884.8M | |
$1,108,102,085 | 66 | 36.91% | $755.04M | |
$11,663,618 | 57 | 32.20% | $934.29M |
| Increased Positions | 118 | +63.78% | 4M | +23.93% |
| Decreased Positions | 86 | -46.49% | 2M | -15.73% |
| New Positions | 53 | New | 854,820 | New |
| Sold Out Positions | 24 | Sold Out | 1M | Sold Out |
| Total Postitions | 217 | +17.3% | 16M | +8.2% |
| Blackrock, Inc. | $72,152.00 | 9.58% | 1.72M | +99,128 | +6.1% | 2025-09-30 |
| Vanguard Group Inc | $43,634.00 | 5.8% | 1.04M | -9,748 | -0.93% | 2025-09-30 |
| Goldman Sachs Group Inc | $30,830.00 | 4.1% | 737,035 | +554,786 | +304.41% | 2025-09-30 |
| Armistice Capital, Llc | $30,285.00 | 4.02% | 724,000 | -876,000 | -54.75% | 2025-09-30 |
| Acadian Asset Management Llc | $28,684.00 | 3.81% | 685,718 | +62,714 | +10.07% | 2025-09-30 |
| Marshall Wace, Llp | $25,154.00 | 3.34% | 601,333 | +232,383 | +62.98% | 2025-09-30 |
| Capitolis Liquid Global Markets Llc | $24,745.00 | 3.29% | 591,553 | 0 | 0% | 2025-09-30 |
| State Street Corp | $23,187.00 | 3.08% | 554,318 | -45,863 | -7.64% | 2025-09-30 |
| Renaissance Technologies Llc | $19,836.00 | 2.63% | 474,209 | +237,763 | +100.56% | 2025-09-30 |
| Geode Capital Management, Llc | $17,724.00 | 2.35% | 423,723 | +8,116 | +1.95% | 2025-09-30 |